What the research found

A 2026 study of 279 women (average age 56, average BMI 24.8) who were already on estrogen-based hormone therapy examined persistent symptoms despite controlled hot flashes. Nearly all participants reported fatigue (93%), low libido (90%), memory problems (89%), and concentration difficulties (86%)—and notably, a substantial portion rated these as severely bothersome (libido 63%, fatigue 48%, memory 38%), whereas only 6% found their controlled hot flashes problematic.

When transdermal testosterone (5 mg daily) was added to their existing regimen, symptom reassessment at an average of 116 days showed improvements across 15 of 24 measured symptoms. Six symptom clusters improved: energy, musculoskeletal function, mood, cognition, genitourinary health, and endocrine markers. Neuropathic and cardiopulmonary symptoms did not change.

Why it matters for you

If you're tracking biomarkers on TRT or HRT, this suggests a common clinical scenario: symptom resolution for one problem (vasomotor instability) can mask another hormonal insufficiency. The breadth of improvements—spanning fatigue, cognition, and musculoskeletal pain—points toward tissue-level effects rather than a single mechanism, since testosterone receptors are present in muscle, bone, brain, and vascular tissue.

For women on estrogen therapy who track sleep quality, energy, or cognitive performance in MyKine and see persistent gaps, baseline testosterone measurement becomes a concrete question to ask your provider. The study used a modest 5 mg daily dose, which differs vastly from male formulations (typically 10× higher) and highlights why precise dosing and titration matter—and why off-label prescribing remains the norm outside Australia.

Caveats

  • No control or placebo group: All participants knew they'd started something new; improvement could reflect expectation or non-specific time effects
  • Retrospective chart review: Reliant on documented outcomes rather than prospective measurement
  • Short follow-up: 116 days acknowledged by authors as insufficient to capture full response trajectory
  • Safety data absent: No measurement of lipids, hematocrit, or androgenic side effects
  • Narrow cohort: Average BMI 24.8 and access to specialist menopause care; findings may not generalise to higher BMI, older/younger age groups, or those without specialist access
  • Regulatory gap: No licensed female testosterone formulation outside Australia creates consistency and long-term outcome data problems